Department of Psychiatry and Behavioral Sciences, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
Department of Psychiatry and Behavioral Sciences, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
J Sex Med. 2019 Sep;16(9):1398-1408. doi: 10.1016/j.jsxm.2019.05.013. Epub 2019 Jul 2.
Despite the importance of using penile injections as part of a penile rehabilitation program, men have difficulty complying with these programs.
To test a novel psychological intervention based on Acceptance and Commitment Therapy for erectile dysfunction (ACT-ED) to help men utilize penile injections.
This pilot randomized controlled trial (RCT) recruited men who were beginning a standard care (SC) structured penile rehabilitation program following radical prostatectomy. The SC program instructed patients to use penile injections 2 to 3 times per week. Participants were randomized to SC+ACT-ED or SC+enhanced monitoring (EM). Over 4 months, patients in the SC+ACT-ED group received SC plus 4 ACT sessions and 3 ACT phone calls; those in the EM group received SC plus 7 phone calls from an experienced sexual medicine nurse practitioner. Participants were assessed at study entry and at 4 and 8 months. For this pilot study, the goal was to determine initial efficacy (ie, effect sizes, where d = 0.2 is small, d = 0.5 is medium, and d = 0.8 is large).
Primary outcomes were feasibility and use of penile injections. Secondary outcomes were ED treatment satisfaction (ie, Erectile Dysfunction Inventory of Treatment Satisfaction, or EDITS), sexual Self-Esteem and Relationship (SEAR) quality, sexual bother (SB), and prostate cancer treatment regret.
The 53 participants were randomized (ACT, n = 26; EM, n = 27). The study acceptance rate was 61%. At 4 months, the ACT-ED group utilized more penile injections per week (1.7) compared to the EM group (0.9) (d = 1.25; P = .001) and was more adherent to penile rehabilitation compared to the EM group (ACT, 44%; EM, 10%; relative risk [RR], 4.4; P = .02). These gains were maintained at 8 months for injections per week (ACT, 1.2; EM, 0.7; d = 1.08; P = .03) and approached significance for adherence (ACT, 18%; EM, 0%; P = .10). At 4 months, ACT-ED, compared to EM, reported moderate effects for greater satisfaction with ED treatment (d = 0.41; P = .22), greater sexual self-esteem (d = 0.54; P = .07) and sexual confidence (d = 0.48; P = .07), lower sexual bother (d = 0.43; P = .17), and lower prostate cancer treatment regret (d = 0.74; P = .02). At 8 months, moderate effects in favor of ACT-ED were maintained for greater sexual self-esteem (d = 0.40; P = .19) and less treatment regret (d = 0.47; P = .16).
ACT concepts may help men utilize penile injections and cope with the effects of ED.
Strengths include use of an innovative intervention utilizing ACT concepts and pilot RCT. Limitations include the pilot nature of the study (eg, small samples size, lack of statistical power).
ACT-ED is feasible and significantly increases the use of penile injections. ACT-ED also shows promise (moderate effects) for increasing satisfaction with penile injections and sexual self-esteem while decreasing sexual bother and prostate cancer treatment regret. Nelson CJ, Saracino RM, Napolitano S, et al. Acceptance and Commitment Therapy to Increase Adherence to Penile Injection Therapy-Based Rehabilitation After Radical Prostatectomy: Pilot Randomized Controlled Trial. J Sex Med 2019; 19:1398-1408.
尽管阴茎注射作为阴茎康复计划的一部分很重要,但男性在遵守这些计划方面存在困难。
测试一种基于接受与承诺疗法(ACT)的新型心理干预措施,以帮助男性使用阴茎注射。
这项初步随机对照试验(RCT)招募了正在接受标准护理(SC)结构阴茎康复计划的根治性前列腺切除术后男性。SC 计划指导患者每周使用阴茎注射 2 到 3 次。参与者被随机分配到 SC+ACT-ED 或 SC+增强监测(EM)组。在 4 个月内,SC+ACT-ED 组的患者接受了 SC 加 4 次 ACT 疗程和 3 次 ACT 电话;EM 组的患者接受了来自经验丰富的性医学护士从业者的 7 次电话。参与者在研究开始时和 4 个月和 8 个月时进行评估。对于这项初步研究,目标是确定初步疗效(即效果大小,其中 d=0.2 为小,d=0.5 为中,d=0.8 为大)。
主要结果是阴茎注射的可行性和使用情况。次要结果是 ED 治疗满意度(即治疗满意度问卷,EDITS)、性自尊和关系(SEAR)质量、性困扰(SB)和前列腺癌治疗后悔。
53 名参与者被随机分配(ACT,n=26;EM,n=27)。研究接受率为 61%。在 4 个月时,ACT-ED 组每周使用的阴茎注射次数(1.7)多于 EM 组(0.9)(d=1.25;P=0.001),并且比 EM 组更遵守阴茎康复计划(ACT,44%;EM,10%;相对风险 [RR],4.4;P=0.02)。这些收益在 8 个月时保持不变,每周注射次数(ACT,1.2;EM,0.7;d=1.08;P=0.03),并且在遵守方面接近显著(ACT,18%;EM,0%;P=0.10)。在 4 个月时,与 EM 相比,ACT-ED 报告了对 ED 治疗满意度更大的中度影响(d=0.41;P=0.22)、更高的性自尊(d=0.54;P=0.07)和性自信(d=0.48;P=0.07)、更低的性困扰(d=0.43;P=0.17)和更低的前列腺癌治疗后悔(d=0.74;P=0.02)。在 8 个月时,ACT-ED 的中度效果仍然有利于更高的性自尊(d=0.40;P=0.19)和更少的治疗后悔(d=0.47;P=0.16)。
ACT 概念可能有助于男性使用阴茎注射和应对 ED 的影响。
优势包括使用创新的干预措施,利用 ACT 概念和初步 RCT。局限性包括研究的初步性质(例如,样本量小,缺乏统计能力)。
ACT-ED 是可行的,并且显著增加了阴茎注射的使用。ACT-ED 还显示出有希望的结果(中度效果),可以提高对阴茎注射的满意度和性自尊,同时降低性困扰和前列腺癌治疗后悔。